ArticleMethods in molecular biology (Clifton, N.J.)2026
Use of Microbial Microarrays to Define Antibody Specificity.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The formation of alloantibodies against red blood cell (RBC) antigens is the most frequent immune barrier to blood transfusion. Among these antibodies, those that occur naturally within the first few months of life against carbohydrate-based ABO blood group antigens are the most prevalent. Individuals who lack the A or B antigen produce antibodies directed against the corresponding absent antigen. Unlike antibodies that arise following antigen exposure during pregnancy or transfusion, these spontaneously occurring antibodies suggest a role for environmental influences. Early investigations proposed that microbial pathogens bearing carbohydrate motifs resembling blood group antigens could provide such a stimulus. However, characterizing antibody specificities against diverse microbes remains difficult, as each organism often requires unique growth conditions. To address this challenge, glycan microarray technology has been developed, which has enabled high-throughput assessment of antibody binding to a wide variety of microbial carbohydrate determinants, including those mimicking blood group antigens. In this work, we highlight the use of microbial glycan microarrays for defining specificity of antibodies and lectins against microbial mimics of blood group and related antigens.
Indexed as
Identifiers
42681433What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.